Yes inhibitors, such as dasatinib and saracatinib [15], have been shown to be active in preclinical studies of cancer cell lines with increased YAP1 transcription target expression due to increased β-catenin [14, 16] and therefore, could be an attractive potential therapeutic target in cancer cell lines with a deficiency in the Hippo signaling pathway. This evidence concerns the gene YAP1 and cancer.